

# Luohai Chen

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8861356/luohai-chen-publications-by-year.pdf>

**Version:** 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

15  
papers

80  
citations

7  
h-index

8  
g-index

18  
ext. papers

125  
ext. citations

3.9  
avg, IF

2.48  
L-index

#	Paper	IF	Citations
15	Development of a novel scoring system based on endoscopic appearance for management of rectal neuroendocrine tumors. <i>Endoscopy</i> , <b>2021</b> , 53, 702-709	3.4	2
14	Genetic Characteristics of Colorectal Neuroendocrine Carcinoma: More Similar to Colorectal Adenocarcinoma. <i>Clinical Colorectal Cancer</i> , <b>2021</b> , 20, 177-185.e13	3.8	8
13	Lu-DOTATATE in older patients with metastatic neuroendocrine tumours: safety, efficacy and health-related quality of life. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2021</b> , 48, 3582-3594	8.8	54
12	Myeloid-derived suppressor cells in gastroenteropancreatic neuroendocrine neoplasms. <i>Endocrine</i> , <b>2021</b> , 71, 242-252	4	2
11	The Role of Ki-67 Index Cut-off of 55% and Differentiation in Redefining NET and NEC for Grade 3 Gastrointestinal Neuroendocrine Neoplasms. <i>Journal of Gastrointestinal Surgery</i> , <b>2020</b> , 24, 2302-2305	3.3	1
10	Concordance Between the Ki-67 Index Cutoff Value of 55% and Differentiation in Neuroendocrine Tumor and Neuroendocrine Carcinoma in Grade 3 Pancreatic Neuroendocrine Neoplasms. <i>Pancreas</i> , <b>2020</b> , 49, 1378-1382	2.6	7
9	Quantitative Pretreatment CT Parameters as Predictors of Tumor Response of Neuroendocrine Tumor Liver Metastasis to Transcatheter Arterial Bland Embolization. <i>Neuroendocrinology</i> , <b>2020</b> , 110, 697-704	5.6	1
8	Perspective of neo-adjuvant/conversion and adjuvant therapy for pancreatic neuroendocrine tumors. <i>Journal of Pancreatology</i> , <b>2019</b> , 2, 91-99	1.9	1
7	ASO Author Reflections: Lymphatic Metastasis of Small Bowel Neuroendocrine Tumors. <i>Annals of Surgical Oncology</i> , <b>2019</b> , 26, 555-556	3.1	
6	Loss of expression and prognosis value of alpha-internexin in gastroenteropancreatic neuroendocrine neoplasm. <i>BMC Cancer</i> , <b>2018</b> , 18, 691	4.8	8
5	Exploration of the Exact Prognostic Significance of Lymphatic Metastasis in Jejunoileal Neuroendocrine Tumors. <i>Annals of Surgical Oncology</i> , <b>2018</b> , 25, 2067-2074	3.1	14
4	CT evaluation of response in advanced gastroenteropancreatic neuroendocrine tumors treated with long-acting-repeatable octreotide: what is the optimal size variation threshold?. <i>European Radiology</i> , <b>2018</b> , 28, 5250-5257	8	2
3	A Refined Staging Model for Resectable Pancreatic Ductal Adenocarcinoma Incorporating Examined Lymph Nodes, Location of Tumor and Positive Lymph Nodes Ratio. <i>Journal of Cancer</i> , <b>2018</b> , 9, 3507-3514	4.5	9
2	Clinicopathological features and prognostic validity of WHO grading classification of SI-NENs. <i>BMC Cancer</i> , <b>2017</b> , 17, 521	4.8	8
1	The role of elevated serum procalcitonin in neuroendocrine neoplasms of digestive system. <i>Clinical Biochemistry</i> , <b>2017</b> , 50, 982-987	3.5	11